Nuvalent Acquisition Under Fire – Law Firm Probes $124/shr GSK Deal

What happened

Kahn Swick & Foti (KSF) has launched an investigation into the proposed sale of Nuvalent to GSK for $124 per share, questioning the adequacy of the price and the sale process. This adds a layer of uncertainty to a stock that was trading around $97, well below the offer, suggesting the market had already priced in some deal risk. Our DeepValue report rated Nuvalent a WAIT with a base case of $105 and bull case of $135, placing the $124 offer within plausible upside but leaving no margin for regulatory slippage. The KSF probe could pressure the board to demonstrate a fair process or attract a competing bidder, but it also raises the risk of renegotiation or delay. For now, the stock trades at a discount to the offer, reflecting ongoing uncertainty about the deal's likelihood and terms.

Implication

The acquisition at $124 validates Nuvalent's pipeline but caps upside absent a higher bid. The investigation introduces binary outcomes: a higher price or a deal collapse. Given the prior WAIT rating, a disciplined approach is to hold or take the spread if the deal seems likely, but be prepared for volatility as the investigation unfolds.

Thesis delta

The prior thesis centered on waiting for neladalkib NDA submission and zidesamtinib PDUFA to drive value. The proposed cash offer at $124 preempts those catalysts, shifting the focus to M&A dynamics: the stock's near-term value is now tied to the deal outcome, not pipeline execution. The risk-reward has moved from a regulatory binary to a deal-adequacy binary, with the KSF probe adding a new layer of uncertainty.